Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET
Crossref DOI link: https://doi.org/10.1186/s13063-024-08146-1
Published Online: 2024-05-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Singh, Simron
Ferone, Diego
Capdevila, Jaume
Chan, Jennifer Ang
de Herder, Wouter W.
Halperin, Daniel
Mailman, Josh
Hellström, Lisa
Liedman, Hanna
Svedberg, Agneta
Tiberg, Fredrik
Text and Data Mining valid from 2024-05-02
Version of Record valid from 2024-05-02
Article History
First Online: 2 May 2024